trending Market Intelligence /marketintelligence/en/news-insights/trending/kj8Ogzd9AZ01wYuSCDr5tA2 content esgSubNav
In This List

Dynavax reports positive phase 1b/2 data for skin cancer treatment

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Dynavax reports positive phase 1b/2 data for skin cancer treatment

Dynavax Technologies Corp. reported positive results from the dose escalation phase of an ongoing phase 1b/2 study for its drug SD-101 in combination with Merck & Co. Inc.'s Keytruda in patients with metastatic melanoma, or skin cancer.

In 7 anti-PD-1/L1-naïve patients, SD-101 used in combination with Keytruda resulted in a 100% overall response rate and a 29% complete response rate, versus Keytruda as monotherapy which showed 33% overall response rate and a 6% complete response.

In 12 patients with advanced melanoma who had failed anti-PD-1 treatment, the introduction of SD-101 caused tumor shrinkage in 42% patients, with 17% having a partial response, indicating an anti-tumor immune response generated by SD-101.

The drug combination mobilized both innate and adaptive immune response in study participants. Tumor shrinkage was also observed in non-injected visceral lesions.